Gila Bronner

Background: A range of impulse control disorders has been described in Parkinson's disease, including compulsive sexual behavior. Excessive sexual demands of parkinsonian men can lead to considerable tension within the couple. Thorough sexual interviews reveal that these cases may reflect various types of sexual dysfunctions that present as hypersexuality. Objective: This study aims to analyze cases of presumed and true compulsive male sexual behavior, and to propose a practical tool for clinicians, assisting them with the diagnosis and management of compulsive sexual behavior and other sexual dysfunctions in parkinsonian patients. Methods: We describe four male patients with Parkinson's disease from the movement disorders clinic, which were referred to the sex therapist as suspected hypersexuality. Results: The sexual assessment revealed that only one of the cases involved true hypersexuality due to compulsive sexual behavior. The other three presented with erectile dysfunction, difficulties reaching orgasm (delayed ejaculation), and a gap in desire within the couple. Conclusions: Complaints about hypersexual behavior in patients with Parkinson's disease must be carefully evaluated, involving a multidisciplinary team. A comprehensive diagnostic and therapeutic algorithm is suggested.

Nonmotor symptoms, among them sexual dysfunction, are common and underrecognized in patients with Parkinson disease; they play a major role in the deterioration of quality of life of patients and their partners. Loss of desire and dissatisfaction with their sexual life is encountered in both genders. Hypersexuality (HS), erectile dysfunction and problems with ejaculation are found in male patients, and loss of lubrication and involuntary urination during sex are found in female patients. Tremor, hypomimia, muscle rigidity, bradykinesia, ‘clumsiness’ in fine motor control, dyskinesias, hypersalivation and sweating may interfere with sexual function. Optimal dopaminergic treatment should facilitate sexual encounters of the couple. Appropriate counselling diminishes some of the problems (reluctance to engage in sex, problems with ejaculation, lubrication and urinary incontinence). Treatment of erectile dysfunction with sildenafil and apomorphine is evidence based. HS or compulsive sexual behaviour are side effects of dopaminergic therapy, particularly by dopaminergic agonists, and should be treated primarily by diminishing their dose. Neurologists should actively investigate sexual dysfunction in their Parkinsonian patients and offer treatment, optimally within a multidisciplinary team, where a dedicated professional would deal with sexual counselling.

This study defines characteristics of delayed help-seeking in men who fail phosphodiesterase-5 inhibitors (PDE5I) treatment for their post radical retropubic prostatectomy (RRP) erectile dysfunction (ED). Medical charts were reviewed retrospectively. All men were offered second line treatment with vacuum devices or intracavernous injection (ICI) and sex therapy. This study included thirty one patients. Average age at surgery was 60 years (SD = 5.3, range 46–70). Average period for second line help-seeking was 25.9 months (SD = 12.9, range 3–111). All subjects believed that surgery would not affect their sexual function. Twenty men (65%) used ICI as a second line treatment. Eleven men (35%) declined treatment, waiting for spontaneous recovery. In ICI sub-group, 5 men (25%) regained spontaneous erection within 7–10 months after initial treatment (16–19 months post-surgery). Seven men (35%) responded positively to PDE5I 3–5 months after starting ICI. Three men (15%) used vacuum device. None regained spontaneous erection. All 7 men (23%) who met sex therapist with their partner reported improved sexual life, even if ED wasn't resolved. Patients should receive comprehensive information about sexual recovery, to encourage early ED treatment after RRP and to overcome unwanted misconceptions regarding spontaneous recovery.

Female sexual functioning is a complex process involving physiological, psychosocial and interpersonal factors. Sexual dysfunction (SD) is frequent (40-74%) among women with multiple sclerosis (MS), reflecting neurological dysfunction, psychological factors, depression, side effects of medications and physical manifestations of the disease, such as fatigue and muscle weakness. A conceptual model for sexual problems in MS characterizes three levels. Primary SD includes impaired libido, lubrication, and orgasm. Secondary SD is composed of limiting sexual expressions due to physical manifestations. Tertiary SD results from psychological, emotional, social, and cultural aspects. Sexual problems cause distress and may affect the family bond. Practical suggestions on initiation of discussion of sexual issues for MS patients are included in this review. Assessment and treatment of sexual problems should combine medical and psychosexual approaches and begin early after MS diagnosis. Intervention can be done by recognizing sexual needs, educating and providing information, by letting patients express their difficulties and referring them to specialists and other information resources.

Increasing awareness and medical studies of sexual dysfunction (SD) unveil the multi-dimensional nature of SD and the need for a multidisciplinary treatment approach. To describe the psychosexual contribution to the multidisciplinary model for the assessment and treatment of SD. The psychosexual contribution will be demonstrated by 4 case reports and data of subjects applying for sex therapy during 2004-8. A total of 822 women (age 35 +/- 12.0 years) and 813 men (age 38 +/- 13.2 years) applied for sex therapy; 44% were referred by a physician, 37% found information on the internet or in other media resources. The most frequent SDs in women were: hypoactive sexual desire disorder (HSDD] (29.7%), sexual pain (28.5%) and anorgasmia (20.9%); and in men: erectile dysfunction (44.2%), premature ejaculation (24.5%) and HSDD (17.5%). Co-morbid relationship distress was found in 217 of the cases (26.5%). Subjects, referred by a physician or on their own initiation, present a variety of SDs, stemming from a combination of physical, psychological and interpersonal contributing factors. The presenting sexual problem is frequently the tip of the iceberg of hidden psychological problems, relationship distress or partner's SD. The overall goal of treatment is increased pleasure and satisfaction, rather than achieving a perfect genital response. Therefore, successful treatment outcome depends on multi-professional assessment and successful resolution of the issues that accompany the sexual complaint, sharing the process with patients and their partners.

Premature ejaculation (PE) is one of the most common sexual dysfunctions among men. PE is poorly defined and inadequately characterized, therefore, professionals find it difficult to cope with the diagnosis, treatment and research. Men who complain about their PE also describe their problem in different ways. This article describes the prevalence of PE, presents the different definitions of the problem and provides a model for evaluation and treatment combining medical and psychosexual techniques. The proposed model for the diagnosis and treatment of PE was composed by combining information from relevant literature with the multi-professional staff experience in our Sexual Medicine Center. Selective serotonin release inhibitors (SSRIs) have been the most promising medication for treatment of PE. Psychosexual therapy, offering cognitive-behavioral techniques contribute to the man's ability to improve his sexual and couple relationships. Diagnosis of PE is mainly based on sexual history as described by the male patient. Therefore, it is essential to have a comprehensive medical and sexual history, description of the effect of PE on sexual activity, and the degree of personal and couple distress. It is important to clarify the onset of the problem, as PE may be the result of another sexual dysfunction of the man or his sexual partner.